Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

802.67 +3.34 (+0.42%)
Streaming Delayed Price Updated: 10:20 AM EST, Jan 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
This Huntington Ingalls Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings For argenx ↗
 
Via Benzinga
News headline image
Biotech Stocks : Are You A Trader Or A Longer Term Investor? ↗
Biotech bull market is intact as indicated by large cap biopharma and the best performing funds. 
Via Talk Markets
News headline image
Peeling Back The Layers: Exploring argenx Through Analyst Insights ↗
 
Via Benzinga
News headline image
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases ↗
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads. 
Via Investor's Business Daily
News headline image
Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
What 25 Analyst Ratings Have To Say About argenx ↗
 
Via Benzinga
News headline image
The Analyst Verdict: argenx In The Eyes Of 27 Experts ↗
 
Via Benzinga
News headline image
Breaking Down argenx: 12 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB ↗
Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows... 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
The Analyst Verdict: argenx In The Eyes Of 12 Experts ↗
 
Via Benzinga
News headline image
Key Takeaways From argenx Analyst Ratings ↗
 
Via Benzinga
News headline image
Why Is European Drugmaker Argenx Stock Trading Higher On Monday? ↗
The FDA has approved Argenx's Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy, with projections of $1.2 billion in U.S. revenues by 2030. 
Via Benzinga
News headline image
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval ↗
This is the second approval for the biotech company's drug, Vyvgart Hytrulo. 
Via Investor's Business Daily
News headline image
Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay ↗
Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday. 
Via Investor's Business Daily
News headline image
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study ↗
Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations. 
Via Benzinga
News headline image
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump ↗
The company says it's still running additional testing of the drug, calling the results "positive." 
Via Investor's Business Daily
News headline image
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
ARGX Stock Earnings: argenx Misses EPS, Misses Revenue for Q1 2024 ↗
ARGX stock results show that argenx missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy ↗
Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current... 
Via Benzinga
News headline image
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance. 
Via Benzinga
News headline image
Guess? Posts Upbeat Earnings, Joins Lufax, Nortech Systems And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Thursday. 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.